Targeted nasal vaccination provides antibody-independent protection against Staphylococcus aureus.

Despite showing promise in preclinical models, anti-Staphylococcus aureus vaccines have failed in clinical trials. To date, approaches have focused on neutralizing/opsonizing antibodies; however, vaccines exclusively inducing cellular immunity have not been studied to formally test whether a cellular-only response can protect against infection. We demonstrate that nasal vaccination with targeted nanoparticles loaded with Staphylococcus aureus antigen protects against acute systemic S. aureus infection in the absence of any antigen-specific antibodies. These findings can help inform future developments in staphylococcal vaccine development and studies into the requirements for protective immunity against S. aureus

Memory Th1 Cells Are Protective in Invasive Staphylococcus aureus Infection

Mechanisms of protective immunity to Staphylococcus aureus infection in humans remain elusive. While the importance of cellular immunity has been shown in mice, T cell responses in humans have not been characterised. Using a murine model of recurrent S. aureus peritonitis, we demonstrated that prior exposure to S. aureus enhanced IFNγ responses upon subsequent infection, while adoptive transfer of S. aureus antigen-specific Th1 cells was protective in naïve mice. Translating these findings, we found that S. aureus antigen-specific Th1 cells were also significantly expanded during human S. aureus bloodstream infection (BSI). These Th1 cells were CD45RO+, indicative of a memory phenotype. Thus, exposure to S. aureus induces memory Th1 cells in mice and humans, identifying Th1 cells as potential S. aureus vaccine targets. Consequently, we developed a model vaccine comprising staphylococcal clumping factor A, which we demonstrate to be an effective human T cell antigen, combined with the Th1-driving adjuvant CpG. This novel Th1-inducing vaccine conferred significant protection during S. aureus infection in mice. This study notably advances our understanding of S. aureus cellular immunity, and demonstrates for the first time that a correlate of S. aureus protective immunity identified in mice may be relevant in humans

First evidence of ankylosaurian dinosaurs (Ornithischia: Thyreophora) from the mid-Cretaceous (late Albian-Cenomanian) Winton Formation of Queensland, Australia

First evidence of ankylosaurian dinosaurs (Ornithischia: Thyreophora) from the mid-Cretaceous (late Albian-Cenomanian) Winton Formation of Queensland, Australia. Alcheringa 37, 261-269. ISSN 0311-5518. The first evidence of ankylosaurian thyreophorans from the Winton Formation (late Albian-Cenomanian) of central-western Queensland, Australia, reveals new information about the temporal and palaeobiogeographical range of these dinosaurs within Gondwana. The material, which comprises isolated teeth, is the youngest evidence of ankylosaurs in Australia. Although the Winton teeth exhibit a suite of pleisiomorphic characteristics that are also seen in other Australian and Gondwanan ankylosaur taxa, they are morphologically distinct and very likely represent a new taxon. Their discovery adds to the growing body of evidence indicating that thyreophorans, and in particular ankylosaurians, constitute a diverse and important component of Australia's mid-Cretaceous dinosaur fauna